abstract |
A pharmaceutical composition containing a CCN5 or a fragment thereof, a nucleic acid encoding the CCN5, a vector containing the nucleic acid, or a recombinant cell containing the nucleic acid or the vector, as an active ingredient and its use in preventing or treating retinal diseases are disclosed. The CCN5 prevents fibrotic changes, caused by TGF-β, EEF, or anti-VEGF drugs, in retinal pigment epithelial cells. In addition, CCN5 recuperates the morphological or functional damage, caused by fibrotic changes, of retinal pigment epithelial cells to the level of normal cells. Therefore, the composition containing CCN5 as an active ingredient can be advantageously utilized for preventing or treating retinal diseases. |